
The company’s currently ongoing Phase IIb pre-pivotal clinical study assesses the safety and efficacy of the IUB™ SEAD

By Kate Reger, project assistant at Shake The Dust

The platform provides women with access to birth control, herpes treatment and emergency contraception

Phexxi will be the first and only hormone-free contraceptive offered by Favor

The company's first product is currently undergoing clinical investigation

The company has also announced a EUREKA-EUROSTARS grant co-funded by the Swiss innovation agnecy Innosuisse

The subcutaneous and self-injectable product requires no surgical or specialist intervention, say developers

The grant from the Bill & Melinda Gates Foundation will help Cyclica to advance contraceptive medicines

The platform will include both a hormonal and hormone-free IUD option

This week we meet Keren Leshem, Ocon Healthcare CEO